Zimmer Biomet Holdings, Inc. ZBH
NYSEMedical devicesFinancials to Sep 30, 2026 · Updated Nov 11, 2026
Moat ranks
Balance sheet
| $B | Dec 31 | Sep 30 |
|---|---|---|
| Cash | 0.6 | 0.4 |
| Securities | 0.0 | 0.0 |
| Debt | 7.5 | 7.5 |
| Net cash | -6.9 | -7.1 |
| Equity | 12.7 | 12.7 |
- Debt / EBITDA
- 3.31×
- Debt / equity
- 0.59×
- Leases (12/31/25)
- $233M
- Diluted shares
- 191M
- Book value / share
- $66.43
- Price / book
- 1.6×
- Net cash / share
- −$37.12
- Market cap
- $20.3B
- Enterprise value
- $27.4B
Per-share record
Key indicators
| Indicator | Latest | Vs year ago | Last 8 quarters |
|---|---|---|---|
| Revenue growth | 3.1% | -6.6 pts | |
| Operating margin | 14.9% | -2.6 pts | |
| FCF margin | 16.8% | +3.5 pts | |
| Capex / revenue | 10.3% | +2.8 pts | |
| Knee implant sales per quarter | $768M | -3% | |
| Hip implant sales per quarter | $537M | +6% | |
| S.E.T. sales per quarter | $578M | +7% | |
| Selling price effect | – | -1% | |
| Knee implant sales · 12/31/25 | $3.3B | +5% |
Margins and growth from reported quarters; company KPIs as reported in results releases.
About ZBH
Zimmer Biomet sells joint-replacement implants, sports medicine, extremity and trauma devices, plus robotic, digital and surgical support products. Knees account for about 40% of 2025 sales; hips and S.E.T. each contribute roughly a quarter.
- Design In Qualification
Knee systems require product-specific technique, instruments, training, and OR familiarity.
- Service Field Network
Consignment-heavy inventory and local clinical support improve case readiness and responsiveness.
- Design In Qualification
Hip systems are embedded in procedure-specific technique and instrument workflows, creating moderate retraining and qualification friction.
- Service Field Network
Local field coverage and consigned inventory support case readiness and responsiveness, but no category-specific service retention, response-time, or margin evidence establishes a strong advantage over incumbent peers.
- Sep 8, 2026
Zimmer Biomet announced new Americas and portfolio leadership, with promotions effective October 1 and Kevin Thornal departing September 30; it reaffirmed the August outlook while seeking faster U.S. commercial execution.
- Sep 2, 2026
A federal court denied Zimmer’s effort to end the Morrison hip-implant claims at the pleadings stage and allowed a fraud amendment; the case remains a litigation risk and the ruling sets no damages amount.
- Aug 28, 2026
A federal court granted Zimmer summary judgment in the McMillan hip-implant case and ordered it closed; this resolves that case, not the wider product-liability portfolio.
- Aug 5, 2026
Zimmer Biomet raised 2026 reported sales-growth guidance to 3.9%–4.9% and organic constant-currency guidance to 2.25%–3.25% after Q2 results; acquired sales and currencies still contribute to the gap.
- Apr 28, 2026
CFO Suketu Upadhyay departed and Paul Stellato became interim CFO, creating a finance-leadership transition while the company integrates acquisitions and changes its U.S. sales model.
Ownership
Go deeper on ZBH
- Compare stock research toolsFundamentals, valuation and screening platforms for ZBH.19 tools
- See ZBH's price chartNo price chart here yet. See price history and indicators.17 tools
- Read ZBH's earnings callsTranscripts and audio of results calls, with management's own words.15 tools
- Investing tool dealsCurrent discounts on research, charting and tracking tools.98 deals
On this page
Financial record
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | Trend | Change 2016–25 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Per share ($) | |||||||||||||
| Revenue | 37.89 | 38.31 | 38.98 | 33.67 | 29.60 | 32.45 | 33.00 | 35.26 | 37.66 | 41.43 | 44.78 | +1.0%/yr | |
| Cash flow | 8.06 | 7.77 | 8.59 | 6.72 | 5.20 | 6.67 | 6.45 | 7.54 | 7.35 | 8.54 | 9.85 | +0.6%/yr | |
| Earnings | 1.51 | 8.90 | -1.86 | 5.41 | -0.05 | 2.12 | 1.38 | 4.88 | 4.43 | 3.55 | 4.01 | +9.9%/yr | |
| Free cash flow | 5.44 | 5.35 | 6.43 | 3.49 | 3.40 | 4.65 | 4.33 | 4.17 | 4.43 | 5.64 | 6.05 | +0.4%/yr | |
| Capex | 2.62 | 2.42 | 2.16 | 3.23 | 1.79 | 2.02 | 2.12 | 3.37 | 2.93 | 2.91 | 3.79 | +1.2%/yr | |
| Dividends | 0.93 | 0.95 | 0.96 | 0.95 | 0.96 | 0.95 | 0.96 | 0.96 | 0.96 | 0.96 | 0.98 | +0.3%/yr | |
| Book value | 47.77 | 57.61 | 55.39 | 59.93 | 58.91 | 60.17 | 57.16 | 59.52 | 61.15 | 63.90 | 66.43 | +3.3%/yr | |
| Diluted shares (M) | 202 | 204 | 204 | 207 | 207 | 210 | 210 | 210 | 204 | 199 | 191 | -0.2%/yr | |
| Totals ($B) | |||||||||||||
| Revenue | 7.7 | 7.8 | 7.9 | 7.0 | 6.1 | 6.8 | 6.9 | 7.4 | 7.7 | 8.2 | 8.6 | +0.8%/yr | |
| Operating income | 0.8 | 0.8 | 0.0 | 1.1 | 0.1 | 0.9 | 0.7 | 1.3 | 1.3 | 1.1 | 1.2 | +3.3%/yr | |
| Net income | 0.3 | 1.8 | -0.4 | 1.1 | -0.0 | 0.4 | 0.3 | 1.0 | 0.9 | 0.7 | 0.8 | +9.7%/yr | |
| Free cash flow | 1.1 | 1.1 | 1.3 | 0.7 | 0.7 | 1.0 | 0.9 | 0.9 | 0.9 | 1.1 | 1.2 | +0.2%/yr | |
| Buybacks | 0.4 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.7 | 0.9 | 0.5 | 0.8 | +1.8%/yr | |
| Dividends | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | +0.1%/yr | |
| Net cash | -10.6 | -9.6 | -8.4 | -7.6 | -7.3 | -6.6 | -5.3 | -5.4 | -5.7 | -6.9 | -7.1 | +$3.7B | |
| Margins & returns (%) | |||||||||||||
| Gross margin | 61.6 | 64.9 | 63.8 | 64.9 | 61.9 | 63.5 | 63.3 | 64.2 | 63.8 | 61.6 | 61.9 | +0.1 pts | |
| Operating margin | 10.7 | 10.2 | 0.4 | 16.0 | 1.4 | 12.6 | 10.0 | 17.3 | 16.7 | 13.3 | 13.6 | +2.6 pts | |
| Net margin | 4.0 | 23.2 | -4.8 | 16.1 | -0.2 | 6.5 | 4.2 | 13.8 | 11.8 | 8.6 | 9.0 | +4.6 pts | |
| FCF margin | 14.4 | 14.0 | 16.5 | 10.4 | 11.5 | 14.3 | 13.1 | 11.8 | 11.8 | 13.6 | 13.5 | -0.8 pts | |
| ROIC | 3.6 | 3.4 | 0.2 | 5.0 | 0.4 | 4.0 | 3.6 | 6.4 | 6.4 | 5.0 | 5.3 | +1.4 pts | |
| Return on equity | 3.2 | 15.5 | -3.4 | 9.0 | -0.1 | 3.5 | 2.4 | 8.2 | 7.2 | 5.6 | 6.0 | +2.4 pts | |
| R&D % of revenue | 4.8 | 4.7 | 4.9 | 5.7 | 5.3 | 6.4 | 5.9 | 6.2 | 5.7 | 5.6 | 5.0 | +0.8 pts | |
| Stock pay % of revenue | 0.7 | 0.7 | 0.8 | 1.1 | 1.2 | 1.1 | 1.5 | 1.3 | 1.3 | 1.1 | 1.1 | +0.3 pts | |
| Capex % of revenue | 6.9 | 6.3 | 5.5 | 9.6 | 6.1 | 6.2 | 6.4 | 9.6 | 7.8 | 7.0 | 8.5 | +0.1 pts | |
Change uses 2016 and 2025 only: compound annual growth for amounts, points for margins and returns, and the change in amount for net cash. A dash means no 2016 base. Trend shows the fiscal years.
Moat
Moat scorecard
- Strength
- Confidence
- Structure
- Oligopoly
- Durability
- medium
- Trajectory
- narrowing
- Pricing power
- weak
- Knees40.4%2 claims
- Hips25.4%2 claims
- S.E.T. (Sports Medicine, Extremities, Trauma, CMFT)26.1%1 claim
- Technology & Data, Bone Cement and Surgical8.1%No moat
Moat claims
- Applies to
- Knees
- Confidence
- Durability
- medium
- Trajectory
- narrowingas of Sep 30, 2026
Knee systems require product-specific technique, instruments, training, and OR familiarity. The filing identifies entrenched clinical practice as an adoption barrier, supporting moderate qualification friction, but surgeons can retrain and large health systems can standardize vendors.
Q3 knee sales declined 3.1% reported and 2.6% in constant currency, reflecting competitive pressure and the sales-channel transition. Surgeon training and product qualification have not prevented the setback.
- Knee implant sales$3.3B+5%
- Knee implant sales per quarter$768M-3%
- Selling price effect–-1%
- Hospital standardization reduces surgeon choice
- New implant designs narrow differentiation
- Shift of volume to price-sensitive ambulatory surgery centers
- FilingZimmer Biomet Annual Report (Form 10-K), FY ended 2025-12-31Feb 20, 2026
- Applies to
- Knees
- Confidence
- Durability
- medium
- Trajectory
- narrowingas of Sep 30, 2026
Consignment-heavy inventory and local clinical support improve case readiness and responsiveness. Replicating coverage is costly for a small entrant, but the other major orthopedic vendors operate comparable field and consignment models, limiting differentiation.
Q3 knee sales fell 3.1% while the U.S. sales-channel transformation continues. Case support remains necessary, but current results do not show better retention or coverage.
- Knee implant sales$3.3B+5%
- Knee implant sales per quarter$768M-3%
- Selling price effect–-1%
- Distributor/channel disruption
- ERP/logistics execution issues
- Hospital consolidation reduces the value of local density
- FilingZimmer Biomet Annual Report (Form 10-K), FY ended 2025-12-31Feb 20, 2026
- Applies to
- Hips
- Confidence
- Durability
- medium
- Trajectory
- stableas of Sep 30, 2026
Hip systems are embedded in procedure-specific technique and instrument workflows, creating moderate retraining and qualification friction. This is not a hard lock-in: competitors offer comparable implant families and health systems can consolidate suppliers.
Hip sales grew 6.0% reported and 7.0% in constant currency in Q3, while global prices declined 0.7%. Repeat surgeon demand persists without evidence of greater pricing control.
- Hip implant sales$2.1B+5%
- Hip implant sales per quarter$537M+6%
- Selling price effect–-1%
- Commoditization of stems/cups
- Purchaser-driven standardization and tendering
- FilingZimmer Biomet Annual Report (Form 10-K), FY ended 2025-12-31Feb 20, 2026
- Applies to
- Hips
- Confidence
- Durability
- medium
- Trajectory
- stableas of Sep 30, 2026
Local field coverage and consigned inventory support case readiness and responsiveness, but no category-specific service retention, response-time, or margin evidence establishes a strong advantage over incumbent peers.
Q3 hip sales reached $536.5 million, up 6.0%. The filing does not publish case fill rates, surgeon retention or service productivity that would establish a stronger field network.
- Hip implant sales$2.1B+5%
- Hip implant sales per quarter$537M+6%
- Selling price effect–-1%
- Distributor instability in certain regions
- Execution issues that reduce service levels
- FilingZimmer Biomet Annual Report (Form 10-K), FY ended 2025-12-31Feb 20, 2026
- Applies to
- S.E.T. (Sports Medicine, Extremities, Trauma, CMFT)
- Confidence
- Durability
- medium
- Trajectory
- stableas of Sep 30, 2026
Field support and medical education aid case coverage across procedure types, but category breadth, acquisitions, and salesforce scale do not prove a durable advantage over equally capable orthopedic competitors.
Q3 S.E.T. sales grew 6.8% to $578.3 million. Acquired products broaden the portfolio, while no separate retention or service-performance series proves a widening advantage.
- S.E.T. sales$2.2B+15%
- S.E.T. sales per quarter$578M+7%
- Selling price effect–-1%
- Distributor turnover in smaller markets
- Margin pressure reduces ability to fund field headcount
- FilingZimmer Biomet Annual Report (Form 10-K), FY ended 2025-12-31Feb 20, 2026
Profile change log
- Oct 8, 2026 · business change
Zimmer Biomet announced new Americas and portfolio leadership, with promotions effective October 1 and Kevin Thornal departing September 30; it reaffirmed the August outlook while seeking faster U.S. commercial execution.
- Oct 8, 2026 · business change
A federal court denied Zimmer’s effort to end the Morrison hip-implant claims at the pleadings stage and allowed a fraud amendment; the case remains a litigation risk and the ruling sets no damages amount.
- Oct 8, 2026 · business change
A federal court granted Zimmer summary judgment in the McMillan hip-implant case and ordered it closed; this resolves that case, not the wider product-liability portfolio.
- Oct 8, 2026 · business change
Zimmer Biomet raised 2026 reported sales-growth guidance to 3.9%–4.9% and organic constant-currency guidance to 2.25%–3.25% after Q2 results; acquired sales and currencies still contribute to the gap.
- Oct 8, 2026 · business change
CFO Suketu Upadhyay departed and Paul Stellato became interim CFO, creating a finance-leadership transition while the company integrates acquisitions and changes its U.S. sales model.
- Oct 8, 2026 · business change
Zimmer Biomet bought Monogram, adding CT-based robotic knee technology with commercialization using Zimmer implants expected by early 2027; the acquisition adds development and execution risk before recurring revenue is proved.
- Oct 8, 2026 · business change
Zimmer Biomet completed the Paragon 28 acquisition, adding a foot-and-ankle portfolio and sales force; acquired growth, integration costs and low goodwill headroom now need to be tested against cash returns.
- Oct 8, 2026 · business change
Zimmer Biomet spun off ZimVie’s spine and dental businesses, concentrating the remaining company on joint reconstruction and related orthopedic products.
- Oct 8, 2026 · analyst revision
Updated knee share from 30.1% in 2023 to an industry estimate of 29.6% in 2025 and retained the earlier estimate. Classified the mixed technology/cement/surgical category as competitive because rival platforms and separate consumable economics do not establish an oligopoly across the whole category.
- Oct 8, 2026 · analyst revision
Changed product revenue weights from Q2 2026 to FY2025: knees 40.36%, hips 25.43%, S.E.T. 26.12% and technology/cement/surgical 8.09%. Added trajectories, management, debate and linked market profiles. The original five claim scores and verified-no-moat status remain; newer industry share estimates support narrowing knee protection.
Industry & peers
Peer map
Hover a point for its values; click a peer to compare. Dashed lines: industry medians.
Global knee reconstruction
Implants, instruments and surgical-assistance systems used to replace or revise failed knee joints worldwide. Excludes other joints, spine implants and general soft-tissue surgery.
| Stocks | Moat | Gross m. | Op. m. | |
|---|---|---|---|---|
| ZBH | 53 | 61.9% | 13.6% | |
| Industry median | 14 | 75 | 52.1% | 13.3% |
| Sector median | 55 | 76 | 61.5% | 17.3% |
| All stocks median | 398 | 76 | 53.1% | 20.0% |
Moat medians cover every stock. Margin medians count only stocks with collected numbers and need at least three.
Drivers & risks
- Ageing populations and osteoarthritis support replacement demand; the main limit is treatment access and surgical capacity.
- Movement to outpatient surgery and ambulatory centers changes inventory, instrument and service needs and creates demand for faster procedures.
- Robotics, navigation and improved implant designs can win surgeon adoption and redirect share among established vendors.
- Hospital purchasing groups, reimbursement limits and government tenders restrict price increases despite clinical preference.
- Staff shortages and elective-procedure deferrals can delay sales even when patients still need surgery.
- Device recalls, liability claims and stricter quality requirements can damage trust and disrupt supply.
- Currency swings, tariffs and higher manufacturing costs affect multinational suppliers; rates also affect hospitals’ robotic capital budgets.
Bulls & bears
Can product launches and the U.S. sales-channel overhaul stop knee share loss and convert acquired growth into durable organic growth and cash generation?
Arguments
What to watch
- 1Knee and hip sales against peer and market growth, using like-for-like currency and acquisition definitions
- 2Selling-price effect and instrument/inventory investment needed to support case coverage
- 3Operating cash flow, acquired-business performance, debt and foot-and-ankle goodwill headroom
Next check: Q4 and FY2026 results: test knee recovery, channel retention, pricing and acquired-business cash returns. Monitor foot-and-ankle impairment headroom and legal proceedings. A results date is not confirmed.
Sources: company filings and dated sources collected for Find My Moat; market cap as of Nov 10, 2026. Not investment advice.
Free to reuse, commercially too, with a credit link. See the data license.
Moat Score 53/100 by <a href="https://www.findmymoat.com/stocks/XNYS:ZBH">Find My Moat</a> (as of September 2026)Curation & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.